Developer docs
API playgroundTry for free, no card

Search company profiles

Bio-Synthesis

Full company profile

uuid000aqs8

Namestring
Bio-Synthesis
Legal namestring
Bio-Synthesis Inc
Websiteurl
biosyn.com
Company typeenum
Private
Founded yearint
1984
Descriptiontext

Bio-Synthesis Inc. is a privately held U.S.-based Contract Development and Manufacturing Organization (CDMO) founded in 1984 and headquartered at 800 Mario Court, Lewisville, Texas. The company specializes in custom synthesis and chemistry development services for nucleic acids (DNA, RNA, oligonucleotides, siRNA, antisense oligonucleotides including steric-blocking ASOs, gapmer ASOs, and splice-switching oligonucleotides), peptides, and bioconjugates, serving biotechnology, pharmaceutical, diagnostic, and life science research organizations globally. Under CEO Miguel Castro, the firm operates with 11-50 employees and maintains ISO 9001:2015 and ISO 13485:2016 certifications, supporting workflows from research use through therapeutic development with GLP/GMP-aligned documentation.

The company's core technology platform integrates solid-phase oligonucleotide synthesis with an unusually broad modification chemistry portfolio, including phosphorothioate, 2'-OMe, 2'-MOE, 2'-F, LNA/BNA, cEt, PMO/PNA, TMO, PACE, and PN backbones, as well as chiral/stereopure configurations. Service lines are organized under the OligoTech at BSI and PeptideTech at BSI sub-brands, complemented by bioconjugation, molecular biology, analytical/QC, bioanalytical, immuno-chemistry, and formulation services including LNP encapsulation for RNA and protein delivery. Production capacity spans µmol screening lots through kilo-class manufacturing, with documented capability for batches up to 100 g in ASO development. The firm reports over 100,000 successful projects completed across 45+ years of operation.

Bio-Synthesis generates revenue on a project-based, quote-driven professional services model. Pricing is determined per project based on sequence complexity, chemistry platform, scale, purification requirements (HPLC, UPLC, PAGE), and QC documentation level, with no publicly listed tiered pricing. Distribution is direct: customers engage through online quote request forms, phone (800.227.0627), email (info@biosyn.com), and consultative scientific engagement via the 'Speak to a Scientist' channel. Marketing is content-driven and educational, leveraging scientific calculators and a literature vault to attract biotech and pharma prospects. The firm is independently owned with no disclosed parent company, no identified venture capital backing, and no public listing.

Short descriptiontext

Bio-Synthesis is a privately held U.S.-based custom synthesis CDMO founded in 1984, specializing in nucleic acids, peptides, and bioconjugates for biotechnology, pharmaceutical, diagnostic, and life science research organizations globally from its Lewisville, Texas facility.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersLewisville, United States
HQ citystring
Lewisville
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
Custom oligonucleotide synthesis, Custom peptide synthesis, Bioconjugation services, Antisense oligonucleotide manufacturing, CDMO chemistry services
Industry2 codes
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)
NAICS code2 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Pharmaceutical Preparation Manufacturing325412
SIC code2 codes
  • Services-Commercial Physical & Biological Research8731
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Contract Manufacturing - Nucleic Acid Therapeutics
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model1 record
1Custom Synthesis CDMO Services
TypeProfessional Services
Description

Bio-Synthesis generates revenue through custom synthesis and chemistry development services for nucleic acids, peptides, and bioconjugates. Services span research scale through GMP manufacturing, with pricing based on sequence complexity, chemistry requirements, scale (from µmol screening lots through gram/kilo production), purification methods (HPLC, UPLC, PAGE), and QC documentation needs. The company supports RUO through GLP/GMP-aligned workflows with project-based pricing.

biosyn.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain
Pricing details1 tier
1Quote-based custom pricing for all service tiers
ModelOtherBilling cadencePay-as-you-go
Notes

No tiered pricing is publicly listed. Customers request quotes specifying sequence, chemistry platform (ASO, SSO, gapmer, peptide, etc.), modification patterns, scale (µmol, mg, gram, kilo), purification requirements (HPLC, UPLC, PAGE), QC documentation level, and any conjugation or delivery needs. Pricing is determined per project based on complexity, chemistry, and volume requirements.

biosyn.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1OligoTech at BSI
Description

Service platform for oligonucleotide synthesis services including custom DNA, RNA, oligonucleotides, siRNA, ASOs, modified oligos, probes, primers, and specialty nucleic acid constructs.

biosyn.com
+1 more record
Core offering1 text field

Bio-Synthesis operates as a Contract Development and Manufacturing Organization (CDMO) providing custom synthesis and chemistry development services for nucleic acids (DNA, RNA, oligonucleotides, siRNA, ASOs, SSOs, gapmers), peptides, and bioconjugates from research scale through GMP manufacturing. The company supports pharmaceutical, biotechnology, diagnostic, and life science research organizations with advanced modification chemistries including PNA, PMO, LNA/BNA, NMA, and other specialty platforms.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 2 values shown
  • 45+ years of expertise supporting over 100,000 custom synthesis projects
+1 more record
Product overview1 text field

Bio-Synthesis operates as an integrated CDMO (Contract Development and Manufacturing Organization) platform offering custom synthesis, chemistry development, and therapeutic development support for nucleic acids, peptides, and bioconjugates. The core product portfolio centers on three main service platforms: OligoTech at BSI (encompassing oligonucleotide synthesis, ASO/SSO/Gapmer manufacturing, and specialty chemistry platforms including PNA, PMO, and advanced modified oligonucleotides), PeptideTech at BSI (providing custom peptide synthesis, peptide bioconjugation, and catalog peptides), and Bioconjugation Services (covering peptide-oligo conjugates, drug conjugates, and polymer conjugates). These are supported by Molecular Biology Services (cloning, gene synthesis, protein expression), Analytical & QC Services, Bioanalytical Services, Immuno Chemistry Services, and Formulation & Product Development including LNP encapsulation. The platform serves research through therapeutic development with scalable production capabilities and integrates scientific tools for oligonucleotide and peptide design.

Product and service9 records
1OligoTech at BSI
CategoryOligonucleotide CDMO Services
Description

Flagship custom oligonucleotide synthesis platform offering DNA, RNA, siRNA, ASO, SSO, and gapmer manufacturing with advanced modification chemistries for biotech, pharma, diagnostic, and research customers.

2PeptideTech at BSI
CategoryPeptide CDMO Services
Description

Custom peptide synthesis service covering standard and modified peptides with analytical support, targeted at therapeutic, diagnostic, and research applications.

3Bioconjugation Services
CategoryBioconjugation Services
Description

Custom bioconjugation services linking oligonucleotides, peptides, small molecules, dyes, and carriers to support targeted therapeutic and diagnostic conjugate development.

4Molecular Biology Services
CategoryMolecular Biology Services
Description

Supporting molecular biology offerings including cloning, mutagenesis, and gene synthesis for research and discovery-stage organizations.

5Analytical & QC Services
CategoryAnalytical & QC Services
Description

Analytical and quality control services supporting custom synthesis programs, including LC-MS, HPLC, and release testing across research and GMP production batches.

6Formulation & Product Development
CategoryFormulation Services
Description

Formulation, product development, and LNP encapsulation services supporting downstream therapeutic and diagnostic product development.

7Splice-Switching Oligonucleotide (SSO) Manufacturing
CategoryOligonucleotide CDMO Services
Description

Specialized manufacturing of splice-switching oligonucleotides, a distinct ASO modality for therapeutic splice modulation programs.

8Steric-Blocking ASO Synthesis
CategoryOligonucleotide CDMO Services
Description

Custom synthesis of steric-blocking antisense oligonucleotides for translational and preclinical therapeutic programs.

9Gapmer ASO Synthesis
Scale indicator5 records

Each record includes

Type, Value, Description, Source

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeBroad incumbent
Description

Agilent offers custom oligonucleotide manufacturing through its Resolution Bioscience and genomics solutions, alongside its broader analytical instruments and life sciences portfolio. Larger incumbent serving overlapping customers in custom oligo and diagnostic probe markets.

TypeDirect peer
Description

Bachem is a leading peptide and oligonucleotide CDMO serving pharmaceutical and biotech customers worldwide, with deep specialization in GMP peptide API manufacturing. Comparable to Bio-Synthesis' PeptideTech platform and therapeutic-grade peptide offerings, with significantly larger commercial-scale capacity.

3Nitto Denko Avecia
TypeDirect peer
Description

Avecia (Nitto Denko Avecia) is a leading oligonucleotide CDMO providing process development, scale-up, and GMP manufacturing for therapeutic nucleic acids. Directly comparable to Bio-Synthesis' therapeutic oligo CDMO offering with substantially larger commercial-scale capacity.

TypeDirect peer
Description

Biolegio is a specialized oligonucleotide CDMO providing custom DNA/RNA oligos, modified oligos, ASOs, siRNA, and GMP-grade nucleic acid manufacturing for therapeutic and diagnostic customers. Closely comparable specialty CDMO peer to Bio-Synthesis in Europe.

TypeBroad incumbent
Description

Thermo Fisher provides custom oligonucleotide and peptide services through its Life Sciences Solutions segment, alongside a much broader CDMO and research products portfolio. A broad incumbent that competes for the same biotech and pharma CDMO customers as Bio-Synthesis at significantly greater scale.

TypeEmerging player
Description

Cytiva (via Precision Nanosystems acquisition) offers LNP encapsulation and mRNA formulation development services and instrumentation. Comparable to Bio-Synthesis' newly added LNP encapsulation service line for RNA/protein delivery formulations.

TypeDirect peer
Description

GenScript provides custom peptide synthesis, gene synthesis, protein expression, and oligonucleotide services through its CDMO and life-science research offerings. Overlaps directly with Bio-Synthesis' PeptideTech and Molecular Biology Services, and competes for biotech CDMO programs.

TypeDirect peer
Description

Eurofins Genomics is a major custom oligonucleotide and gene synthesis service provider within the broader Eurofins Scientific network, serving research and diagnostic customers globally. Directly comparable to Bio-Synthesis across custom DNA/RNA oligo, primer, and probe synthesis.

TypeDirect peer
Description

BioSpring is a specialized oligonucleotide CDMO focused on therapeutic nucleic acid manufacturing, including ASOs, siRNA, and mRNA. A close peer in therapeutic-grade oligo CDMO with comparable chemistry platforms, though operating at significantly larger scale (Frankfurt-based, multi-kg capacity).

TypeDirect peer
Description

IDT is the largest custom oligonucleotide manufacturer globally (now part of Danaher), offering custom DNA/RNA oligos, ASOs, siRNA, and modified oligos to research, diagnostic, and therapeutic customers. Direct competitor to Bio-Synthesis' OligoTech at BSI across the full range of custom nucleic acid synthesis services.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature5 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance2 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Bio-Synthesis

Contract Manufacturing - Nucleic Acid Therapeuticsbiosyn.com

Bio-Synthesis is a privately held U.S.-based custom synthesis CDMO founded in 1984, specializing in nucleic acids, peptides, and bioconjugates for biotechnology, pharmaceutical, diagnostic, and life science research organizations globally from its Lewisville, Texas facility.

What Bio-Synthesis does

Bio-Synthesis Inc. is a privately held U.S.-based Contract Development and Manufacturing Organization (CDMO) founded in 1984 and headquartered at 800 Mario Court, Lewisville, Texas. The company specializes in custom synthesis and chemistry development services for nucleic acids (DNA, RNA, oligonucleotides, siRNA, antisense oligonucleotides including steric-blocking ASOs, gapmer ASOs, and splice-switching oligonucleotides), peptides, and bioconjugates, serving biotechnology, pharmaceutical, diagnostic, and life science research organizations globally. Under CEO Miguel Castro, the firm operates with 11-50 employees and maintains ISO 9001:2015 and ISO 13485:2016 certifications, supporting workflows from research use through therapeutic development with GLP/GMP-aligned documentation.

The company's core technology platform integrates solid-phase oligonucleotide synthesis with an unusually broad modification chemistry portfolio, including phosphorothioate, 2'-OMe, 2'-MOE, 2'-F, LNA/BNA, cEt, PMO/PNA, TMO, PACE, and PN backbones, as well as chiral/stereopure configurations. Service lines are organized under the OligoTech at BSI and PeptideTech at BSI sub-brands, complemented by bioconjugation, molecular biology, analytical/QC, bioanalytical, immuno-chemistry, and formulation services including LNP encapsulation for RNA and protein delivery. Production capacity spans µmol screening lots through kilo-class manufacturing, with documented capability for batches up to 100 g in ASO development. The firm reports over 100,000 successful projects completed across 45+ years of operation.

Bio-Synthesis generates revenue on a project-based, quote-driven professional services model. Pricing is determined per project based on sequence complexity, chemistry platform, scale, purification requirements (HPLC, UPLC, PAGE), and QC documentation level, with no publicly listed tiered pricing. Distribution is direct: customers engage through online quote request forms, phone (800.227.0627), email (info@biosyn.com), and consultative scientific engagement via the 'Speak to a Scientist' channel. Marketing is content-driven and educational, leveraging scientific calculators and a literature vault to attract biotech and pharma prospects. The firm is independently owned with no disclosed parent company, no identified venture capital backing, and no public listing.

Bio-Synthesis firmographics

Firmographics
Name
Bio-Synthesis
Legal name
Bio-Synthesis Inc
Website
https://biosyn.com
Company type
Private
Founded year
1984
Operating status
Operating
Headcount range
11–50 employees
Short description
Bio-Synthesis is a privately held U.S.-based custom synthesis CDMO founded in 1984, specializing in nucleic acids, peptides, and bioconjugates for biotechnology, pharmaceutical, diagnostic, and life science research organizations globally from its Lewisville, Texas facility.
Ownership category
akta.pro rank

Bio-Synthesis industry classification

Industry
Product category
Contract Manufacturing - Nucleic Acid Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical Preparation Manufacturing (325412)
SIC
Services-Commercial Physical & Biological Research (8731), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAGABAF
mRNA/LNP & Nucleic Acid Therapeutics CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGAGAC
mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA)
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Biopharma Manufacturing Services (Biologics/Cell & Gene)

Keywords

  • Custom oligonucleotide synthesis
  • Custom peptide synthesis
  • Bioconjugation services
  • Antisense oligonucleotide manufacturing
  • CDMO chemistry services

Where Bio-Synthesis is headquartered

Location

Headquarters

HQ city
Lewisville
HQ country
United States
HQ region
North America

Offices1 record

Markets served

Bio-Synthesis business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Technology or R&D, Infrastructure, Supply Chain

Revenue model

  1. Custom Synthesis CDMO Services: Bio-Synthesis generates revenue through custom synthesis and chemistry development services for nucleic acids, peptides, and bioconjugates. Services span research scale through GMP manufacturing, with pricing based on sequence complexity, chemistry requirements, scale (from µmol screening lots through gram/kilo production), purification methods (HPLC, UPLC, PAGE), and QC documentation needs. The company supports RUO through GLP/GMP-aligned workflows with project-based pricing.

Pricing tiers

ModelBillingPrice
OtherPay-as-you-goQuote-based custom pricing for all service tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

Bio-Synthesis product offering

Product offering

Core offering

Bio-Synthesis operates as a Contract Development and Manufacturing Organization (CDMO) providing custom synthesis and chemistry development services for nucleic acids (DNA, RNA, oligonucleotides, siRNA, ASOs, SSOs, gapmers), peptides, and bioconjugates from research scale through GMP manufacturing. The company supports pharmaceutical, biotechnology, diagnostic, and life science research organizations with advanced modification chemistries including PNA, PMO, LNA/BNA, NMA, and other specialty platforms.

Product overview

Bio-Synthesis operates as an integrated CDMO (Contract Development and Manufacturing Organization) platform offering custom synthesis, chemistry development, and therapeutic development support for nucleic acids, peptides, and bioconjugates. The core product portfolio centers on three main service platforms: OligoTech at BSI (encompassing oligonucleotide synthesis, ASO/SSO/Gapmer manufacturing, and specialty chemistry platforms including PNA, PMO, and advanced modified oligonucleotides), PeptideTech at BSI (providing custom peptide synthesis, peptide bioconjugation, and catalog peptides), and Bioconjugation Services (covering peptide-oligo conjugates, drug conjugates, and polymer conjugates). These are supported by Molecular Biology Services (cloning, gene synthesis, protein expression), Analytical & QC Services, Bioanalytical Services, Immuno Chemistry Services, and Formulation & Product Development including LNP encapsulation. The platform serves research through therapeutic development with scalable production capabilities and integrates scientific tools for oligonucleotide and peptide design.

Differentiator

Problem solved

Functional benefit

Brands

  • OligoTech at BSI: Service platform for oligonucleotide synthesis services including custom DNA, RNA, oligonucleotides, siRNA, ASOs, modified oligos, probes, primers, and specialty nucleic acid constructs.
  • PeptideTech at BSI

Products and services

  • OligoTech at BSI Flagship custom oligonucleotide synthesis platform offering DNA, RNA, siRNA, ASO, SSO, and gapmer manufacturing with advanced modification chemistries for biotech, pharma, diagnostic, and research customers.
  • PeptideTech at BSI Custom peptide synthesis service covering standard and modified peptides with analytical support, targeted at therapeutic, diagnostic, and research applications.
  • Bioconjugation Services Custom bioconjugation services linking oligonucleotides, peptides, small molecules, dyes, and carriers to support targeted therapeutic and diagnostic conjugate development.
  • Molecular Biology Services Supporting molecular biology offerings including cloning, mutagenesis, and gene synthesis for research and discovery-stage organizations.
  • Analytical & QC Services Analytical and quality control services supporting custom synthesis programs, including LC-MS, HPLC, and release testing across research and GMP production batches.
  • Formulation & Product Development Formulation, product development, and LNP encapsulation services supporting downstream therapeutic and diagnostic product development.
  • Splice-Switching Oligonucleotide (SSO) Manufacturing Specialized manufacturing of splice-switching oligonucleotides, a distinct ASO modality for therapeutic splice modulation programs.
  • Steric-Blocking ASO Synthesis Custom synthesis of steric-blocking antisense oligonucleotides for translational and preclinical therapeutic programs.
  • Gapmer ASO Synthesis

Quantifiable outcome

  • 45+ years of expertise supporting over 100,000 custom synthesis projects
  • +1 more outcomes

Companies that use Bio-Synthesis

Customer profile

Segments4 records

Ideal customer profiles2 records

Bio-Synthesis technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature5 records

Bio-Synthesis partnerships and signals

Strategic signal

Scale indicators5 records

Recent moves5 records

Expansion highlights4 records

Bio-Synthesis competitors and assessment

Company assessment

Broad incumbents

  • Agilent Technologies: Agilent offers custom oligonucleotide manufacturing through its Resolution Bioscience and genomics solutions, alongside its broader analytical instruments and life sciences portfolio. Larger incumbent serving overlapping customers in custom oligo and diagnostic probe markets.
  • Thermo Fisher Scientific: Thermo Fisher provides custom oligonucleotide and peptide services through its Life Sciences Solutions segment, alongside a much broader CDMO and research products portfolio. A broad incumbent that competes for the same biotech and pharma CDMO customers as Bio-Synthesis at significantly greater scale.

Direct peers

  • Bachem: Bachem is a leading peptide and oligonucleotide CDMO serving pharmaceutical and biotech customers worldwide, with deep specialization in GMP peptide API manufacturing. Comparable to Bio-Synthesis' PeptideTech platform and therapeutic-grade peptide offerings, with significantly larger commercial-scale capacity.
  • Nitto Denko Avecia: Avecia (Nitto Denko Avecia) is a leading oligonucleotide CDMO providing process development, scale-up, and GMP manufacturing for therapeutic nucleic acids. Directly comparable to Bio-Synthesis' therapeutic oligo CDMO offering with substantially larger commercial-scale capacity.
  • Biolegio: Biolegio is a specialized oligonucleotide CDMO providing custom DNA/RNA oligos, modified oligos, ASOs, siRNA, and GMP-grade nucleic acid manufacturing for therapeutic and diagnostic customers. Closely comparable specialty CDMO peer to Bio-Synthesis in Europe.
  • GenScript: GenScript provides custom peptide synthesis, gene synthesis, protein expression, and oligonucleotide services through its CDMO and life-science research offerings. Overlaps directly with Bio-Synthesis' PeptideTech and Molecular Biology Services, and competes for biotech CDMO programs.
  • Eurofins Genomics: Eurofins Genomics is a major custom oligonucleotide and gene synthesis service provider within the broader Eurofins Scientific network, serving research and diagnostic customers globally. Directly comparable to Bio-Synthesis across custom DNA/RNA oligo, primer, and probe synthesis.
  • BioSpring: BioSpring is a specialized oligonucleotide CDMO focused on therapeutic nucleic acid manufacturing, including ASOs, siRNA, and mRNA. A close peer in therapeutic-grade oligo CDMO with comparable chemistry platforms, though operating at significantly larger scale (Frankfurt-based, multi-kg capacity).
  • Integrated DNA Technologies (IDT): IDT is the largest custom oligonucleotide manufacturer globally (now part of Danaher), offering custom DNA/RNA oligos, ASOs, siRNA, and modified oligos to research, diagnostic, and therapeutic customers. Direct competitor to Bio-Synthesis' OligoTech at BSI across the full range of custom nucleic acid synthesis services.

Emerging players

  • Cytiva (formerly Precision Nanosystems): Cytiva (via Precision Nanosystems acquisition) offers LNP encapsulation and mRNA formulation development services and instrumentation. Comparable to Bio-Synthesis' newly added LNP encapsulation service line for RNA/protein delivery formulations.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

Bio-Synthesis social profiles

Digital presence

Bio-Synthesis compliance and trust

Trust signal

Compliance2 records

Bio-Synthesis financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Bio-Synthesis leadership team

Management profile

Number of profiles

Profiles1 record

Bio-Synthesis funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Bio-Synthesis M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Bio-Synthesis

What does Bio-Synthesis do?

Bio-Synthesis operates as a Contract Development and Manufacturing Organization (CDMO) providing custom synthesis and chemistry development services for nucleic acids (DNA, RNA, oligonucleotides, siRNA, ASOs, SSOs, gapmers), peptides, and bioconjugates from research scale through GMP manufacturing. The company supports pharmaceutical, biotechnology, diagnostic, and life science research organizations with advanced modification chemistries including PNA, PMO, LNA/BNA, NMA, and other specialty platforms.

Is Bio-Synthesis a public or private company?

Bio-Synthesis is a private company. It is classified as unknown and is currently operating.

When was Bio-Synthesis founded?

Bio-Synthesis was founded in 1984. It employs 11 to 50 people.

Where is Bio-Synthesis based?

Bio-Synthesis is headquartered in Lewisville, United States, in the North America region.

How does Bio-Synthesis make money?

One revenue line is on record: custom Synthesis CDMO Services.

Who are Bio-Synthesis's main competitors?

Broad incumbents on record are Agilent Technologies and Thermo Fisher Scientific. Direct peers are Bachem, Nitto Denko Avecia, Biolegio, GenScript, Eurofins Genomics, BioSpring and Integrated DNA Technologies (IDT). Cytiva (formerly Precision Nanosystems) is listed as an emerging player.

Does Bio-Synthesis have an API?

No public API is recorded for Bio-Synthesis.

What industry is Bio-Synthesis in?

Bio-Synthesis's product category is Contract Manufacturing - Nucleic Acid Therapeutics. Its primary akta.pro industry code is HLAGABAF, mRNA/LNP & Nucleic Acid Therapeutics CDMO, with a secondary code of HLAGAGAC, mRNA & Nucleic Acid Manufacturing Services (mRNA/saRNA/Plasmid DNA). Its NAICS code is 541714 and its SIC code is 8731.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals